Management of tumour lysis syndrome in non-Hodgkin lymphoma

Hong Kong Journal of Paediatrics

Volumn 14, Issue 1, 2009, Pages 11-15

  Cheng, F W T ^a   Xiao, J ^b   Li, C K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Chongqing Children's Hospital   (China)

Author keywords

Non Hodgkin lymphoma; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; ANTINEOPLASTIC AGENT; BICARBONATE; CALCIUM; DIURETIC AGENT; GLUCONATE CALCIUM; NEUTRAL INSULIN; PHOSPHATE BINDING AGENT; PREDNISONE; RASBURICASE; URATE OXIDASE; URICOZYME;

ANAPHYLAXIS; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER GRADING; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FLUID THERAPY; HEMODIALYSIS; HEMOLYSIS; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; INTENSIVE CARE UNIT; LOW DRUG DOSE; METABOLIC DISORDER; METHEMOGLOBINEMIA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR LYSIS SYNDROME; URINE VOLUME;

EID: 59349110462     PISSN: 10139923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting - Airlie House, Virgina, November 1997. J Clin Oncol 1999;17:3835-49.
2. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005; 45:753-69.
3. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-9.
4. Annual workshop. Hong Kong Paediatric Haematology and Oncology Study Group. Unpublished data.
5. Cario MS, Bishop M. Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
6. Hande KR, Garrow GC. Acute tumour lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94: 133-9.
7. Alavi S, Arzanian MT, Abbasian MR, et al. Tumour lysis syndrome in children with non-Hodgkin lymphoma. Paediatr Hematol Oncol 2006;23:65-70.
8. Arseneau JC, Canellos GP, Banks PM, Berard CW, Gralnick HR, DeVita VT Jr. American Burkitt's lymphoma: A clinicoopathologic study of 30 cases. Clinical factors relating to prolonged survival. Am J Med 1975;58:314-21.
9. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyeruricemia and tumor lysis syndrome in patients with acute leukemia and non-Hodgkin's lymphoma in four European countries. Leak Lymphoma 2003; 44:77-83.
10. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumour lysis syndrome: A review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68:486-91.
11. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumour lysis syndrome. Med Pediatr Oncol 1998;31:27-8.
12. Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972;17;890-5.
13. Laboureur P, Langlois C. Urate oxidase of Aspiergillus flavus. Isolation, purification, properties. Bull Soc Chim Biol (Paris) 1968;50:811-25.
14. Rényi I, Bárdi E, Udvardi E, et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and Non-Hodgkin's lymphoma. Pathol Oncol Res 2007;13:57-62.
15. Wang LY, Shih LY, Chang H, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006;115:35-8.
16. Teo WY, Loh TF, Tan AM. Avoiding dialysis in tumor lysis syndrome: Is urate oxidase effective? A case report and review of literature. Ann Acad Med Sigapore 2007;36:679-83.
17. Masera G, Jankovic M, Zurlo MG, et al. Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982:100:152-5.
18. Trifilio S, Tallman M, Singhal S, et al. Low dose recombinant urate oxidase (rasburicase) is effective in hyperuricemia. Blood 2004;104:905a (abstr 3312).
19. Trifilio S, Evens A, Gordon L. Low dose recombinant urate oxidase (rasburicse) is effective in treating hyperuricemia in patients with hematologic malignancies. Blood 2005;106:3123a (abstr).
20. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study. Cancer 2003;98:1048-54.
21. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients. Final results of a multicenter compassionate use trial. Leukemia 2005; 19:34-8.
22. Pui CH, Jeha, Irin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy- associated hyperuricemia in pediatric and adult patients: Results of a compassionate use trial. Leukemia 2001;15:1505-9.
23. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11: 1813-6.
24. Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome.: The role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 1994;8:351-3.
25. Heney D, Essex-Cater A, Brocklebank JT, Bailey CC, Lewis IJ. Continuous arteriovenous haemofiltration in the treatment of tumor lysis syndrome. Pediatr Nephrol 1990;4:245-7.
26. Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. A comparison of inpatient length of stay and costs among patients wit hematological malignancies (excluding Hodgkin's disease) associated with and without acute renal failure. Clin Lymph Myeloma 2008;8:44-51.